SEC Form 4 · accession 0001209191-18-033073
Cidara Therapeutics, Inc. · CDTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Stein
Officer — President & CEO · Director
Period of report
May 23, 2018
Accepted (ET)
May 24, 2018 · 5:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001610618
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 23, 2018 | P | 212,766 | $4.70 | A | 268,320 | D | |
| Common Stock | holding | — | — | — | 203,697 | I | By trust | |
| Common Stock | holding | — | — | — | 420 | I | By son |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant (right to buy)F3 | $6.81 | May 23, 2018 | A | 250,000 | A | May 23, 2018 | — | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1Shares were purchased in a registered direct offering pursuant to a Subscription Agreement dated May 21, 2018.
- F2Includes 3,703 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 18, 2018.
- F3The Warrants will expire upon the earliest of (i) May 23, 2023, (ii) the date that the holder of such Warrant transfers or sells any of the shares of Common Stock purchased by such holder in the first closing of the offering (i.e. May 23, 2018), if such transfer or sale occurs prior to the date that is 120 calendar days following May 23, 2018, (iii) the taking of any short position on the Common Stock by the holder of such Warrant prior to the completion of the second closing of the offering, to be determined, and (iv) the failure by the holder of such Warrant to purchase its pro rata allocation of shares of Common Stock in the second closing of the offering, to be determined.